Status: Recruiting
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.
Participants needed: 1,800
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai JMT-Bio Inc.Updated: Apr 8, 2026Locations: 1
Eligibility criteria
Voluntarily participate and sign the informed consent form. [+14]
History of any prior ipsilateral and/or contralateral invasive breast cancer. [+9]